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Abstract: Nevoid basal cell carcinoma syndrome (NBCCS), or Gorlin syndrome, is a rare hereditary
disease characterized by the development of multiple cutaneous basal cell carcinomas (BCCs) from a
young age.1 Loss-of-function germline mutations in the hedgehog-related patched 1 (PTCH1) tumor
suppressor gene are the most common cause of NBCCS.1 The hedgehog signaling pathway plays a major
role in embryonic development, and in adulthood, is involved in the renewal and maintenance of distinct
tissues, including hair follicles, muscle stem cells, and gastric epithelium.2 Its abnormal activation is
thought to drive the formation of both sporadic BCCs and those resulting from NBCCS.1 Patients with
NBCCS inherit one inactive copy of PTCH1 and then acquire a “second-hit” mutation, resulting in
hedgehog pathway activation and BCC formation.1 Mutations in Suppressor of fused (SUFU) or the
PTCH1 homolog PTCH2 have also been found in a subset of patients meeting criteria for NBCCS.1,3
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Introduction
Nevoid basal cell carcinoma syndrome (NBCCS), or Gorlin syndrome, is
a rare hereditary disease characterized by the development of multiple cuta-
neous basal cell carcinomas (BCCs) from a young age.1 Loss-of-function
germline mutations in the hedgehog-related patched 1 (PTCH1) tumor sup-
pressor gene are the most common cause of NBCCS.1 The hedgehog signaling
pathway plays a major role in embryonic development, and in adulthood, is
involved in the renewal and maintenance of distinct tissues, including hair
follicles, muscle stem cells, and gastric epithelium.2 Its abnormal activation is
thought to drive the formation of both sporadic BCCs and those resulting from
NBCCS.1 Patients with NBCCS inherit one inactive copy of PTCH1 and then
acquire a “second-hit” mutation, resulting in hedgehog pathway activation and
BCC formation.1 Mutations in Suppressor of fused (SUFU) or the PTCH1
homolog PTCH2 have also been found in a subset of patients meeting criteria
for NBCCS.1,3
Treatment of BCCs in patients with NBCCS can be extremely difficult due
to the large number of tumors. Patients with a limited number of BCCs may
benefit from surgical excision.3 However, patients with aggressive or recurrent
tumors, as well as tumors in delicate or high-risk areas, may benefit from
Mohs micrographic surgery, which is lengthy and costly.3 Multiple surgical
procedures can be a source of discomfort, pain, and disfigurement for patients
with NBCCS, leading to an unmet need for nonsurgical and minimally inva-
sive treatment options.
Sonidegib (Odomzo®; Sun Pharmaceutical Industries, Inc.; Cranbury, NJ),
a hedgehog pathway inhibitor (HPI), is approved for the treatment of adult patients
with locally advanced BCC (laBCC) that has recurred following surgery or radia-
tion therapy, or those who are not candidates for surgery or radiation therapy.4
Approval was based on results from the BOLT (BCC outcomes with LDE225
[sonidegib] treatment) study.5,6 Here we report the results of an exploratory study
evaluating the safety, preliminary efficacy, and pharmacokinetics of sonidegib in
patients with NBCCS after 12 weeks of treatment.
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Methods
This phase 2, double-blind, randomized study (NCT0
1350115) adhered to the Declaration of Helsinki and
International Council for Harmonisation Consolidated
Guideline E6 for Good Clinical Practice. Approval to the
study protocol and all amendments was provided by
the Ethics Committees at Erasmus Hospital, UZ Leuven,
the Christian-Albrechts-University of Kiel, and the
University of Vienna; and by the Institutional Review
Board at Aurora, Ontario. All patients provided written
informed consent before enrollment.
Adults with at least two BCCs were eligible to enroll
if they met at least one of the following diagnostic cri-
teria for NBCCS: keratocystic odontogenic tumors, either
from medical history or optional radiography at screen-
ing; at least three palmar and/or plantar pits; history of
bilamellar calcification of the falx cerebri or bifid, fused,
or markedly splayed ribs; first-degree relatives with
NBCCS; and PTCH1 mutation identified in genome
from nontumor tissue. Patients with a histologically con-
firmed diagnosis of laBCC or metastatic BCC (mBCC)
not amenable to radiation therapy or curative surgery
were excluded from the study, as were patients with an
ongoing or recent history of severe, progressive, or
uncontrolled systemic disease. Additional key exclusion
criteria included use of topical treatments for BCCs in the
4 weeks prior to the first dose of study drug; any prior use
of HPI; and use of photodynamic therapy, radiation, or
systemic treatments known to affect BCCs.
Randomization was planned 6:1 to sonidegib 400mg daily
or placebo for 12 weeks. At screening, one target BCC was
selected per patient; the target BCC was a nonrecurring, pre-
viously untreated or unbiopsied BCC 5–20 mm long in
a location amenable to surgical excision. Clinical clearance
of the target BCC was assessed every 2 weeks until the lesion
was excised at week 16. After week 19, patients returned
approximately every 2 months for the next 6 months to assess
tumor burden and safety.
The primary endpoint was target BCC clinical clear-
ance at week 16, with demonstrated ≥60% posterior prob-
ability that ≥50% of the patients receiving sonidegib
exhibited complete clinical clearance. Clinical clearance
was assessed by a blinded, experienced, and qualified
dermatologist who compared the presentation of the target
BCC during the study visit to a macroscopic image of the
BCC at baseline. For consistency, the same investigator
assessed a particular BCC at every study visit. The
response was evaluated on a 6-grade scale from “worsen-
ing” to “complete clearance” (all scale grades summarized
in Table 1), where complete clearance was defined as the
absence of any clinical signs of carcinoma, except post-
inflammatory changes such as erythema, changes in pig-
mentation, or scarring. This approach was designed to be
simple and reproducible and to replicate evaluation of
a BCC in clinical practice.
Secondary assessments included target BCC histological
clearance at week 16 and tumor burden assessed by BCC
counts every 2–4 weeks and at follow-up visits. Safety
Table 1 Efficacy and Safety Outcomes
Efficacy Sonidegib Placebo
n = 7a n = 2
Patients with clinical clearance of target
BCC at week 16b
Complete (100% improvement) 3 (43) 0
Marked (76%–99% improvement) 3 (43) 0
Moderate (26%–75% improvement) 1 (14) 0
Slight (1%–25% improvement) 0 1 (50)
Worsening 0 1 (50)
Patients with histological clearance of
target BCC at week 16
4 (57) 0
Number of total BCCs
Baseline 566 510
Week 12 341 571
Week 16 309 619
Safety n = 8 n = 2
Any AEs (through long-term follow-up
period)
7 (88) 1 (50)
Mild 3 (38) 0
Moderate 3 (38) 0
Severe 1 (13) 1 (50)
Related to treatment 6 (75) 1 (50)
Leading to discontinuation 0 1 (50)
Serious 1 (13) 1 (50)
AEs in ≥20% of patients (core study
period)
Muscle spasms 3 (38) 1 (50)
Alopecia 2 (25) 0
CK increased 2 (25) 0
Fatigue 2 (25) 0
Headache 2 (25) 0
Nasopharyngitis 2 (25) 0
Nausea 2 (25) 0
Notes: Data presented as n (%) of total patients in treatment arm unless otherwise
indicated. aOne patient was excluded from efficacy analysis due to receipt of
placebo in 5 of 13 doses. bOne target BCC was counted per patient and assigned
to 1 of 5 listed clearance categories.
Abbreviations: AE, adverse event; BCC, basal cell carcinoma; CK, creatine kinase.
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assessments included adverse event (AE)monitoring through
the study and for up to 6 months following core study
completion. AE toxicity was graded according to the
National Cancer Institute common terminology criteria for
AEs version 4.0.
Results
Ten patients were enrolled; 8 and 7 completed the core
study and long-term follow-up, respectively (Figure 1).
Due to AEs and laboratory assessment abnormalities, 2
patients discontinued sonidegib treatment on days 65 and
72, respectively. These patients were still included in the
analysis and enrolled in the long-term follow-up, because
they had completed a significant part of the 12-week
treatment period. Median (range) age was 53 (37–68)
years and (range) age was (64–68) years for sonidegib
vs placebo, respectively. Male patients comprised 50%
and 100% of the sonidegib and placebo groups,
respectively.
Complete clinical clearance at week 16 was observed
in 3 of 7 (43%) patients receiving sonidegib (Table 1).
One patient receiving sonidegib was excluded from
analysis due to a protocol deviation. In the placebo
group, 1 (50%) patient exhibited slight clearance at
week 16 and 1 (50%) exhibited worsening. A 35%
posterior probability of the true complete clinical clear-
ance rate being ≥50% was derived from the 43%
observed complete clinical clearance. Since posterior
probability was <60%, the primary endpoint was not
met. At week 16, 4 (57%) patients receiving sonidegib
demonstrated target BCC complete histological clear-
ance vs 0 receiving placebo.
At baseline, the total BCC number in the sonidegib
group was 566 vs 510 for the placebo group (Table 1).
At weeks 12 and 16, the total BCC for the sonidegib
group was 341 and 309, respectively, vs 571 and 619 for
the placebo group. The number of BCCs per patient was
highly variable; the 4 patients with the highest number
of BCCs in the sonidegib group at baseline had between
65 and 214 tumors, while several patients had <5
tumors.
Most AEs were mild-to-moderate (Table 1). One
patient receiving sonidegib experienced a serious AE
(face cellulitis) during the long-term follow-up that was
not suspected to be related to sonidegib. One patient
receiving placebo experienced two serious AEs; worsening
of BCC on the head and residual BCC growth after recent
surgery. No deaths occurred. The most common AE was
Figure 1 Patient disposition.
Notes: aPatients were still included in the analysis and enrolled in long-term follow-up due to completion of most of the treatment period. bOne patient was excluded from
efficacy analysis due to receipt of placebo in 5 of 13 doses.
Abbreviation: BCC, basal cell carcinoma.
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muscle spasms, reported in 3 (38%) and 1 (50%) patients
receiving sonidegib and placebo, respectively. Alopecia
and elevated creatine kinase were each reported in 2
(25%) and 0 patients receiving sonidegib and placebo,
respectively.
Discussion
While the primary efficacy endpoint in this study was not
met, potentially due to small sample size, oral administra-
tion of sonidegib 400 mg daily for 12 weeks resulted in
complete clinical clearance of a target BCC in 3 of 7
patients with NBCCS. The remaining four patients experi-
enced at least moderate clinical clearance. Overall, all
patients receiving sonidegib 400 mg experienced some
clearance of BCC, and no patient receiving sonidegib
had worsening of the target BCC. There was
a discrepancy between clinical and histological BCC clear-
ance, potentially due to remaining erythema or inflamma-
tion confounding clinical evaluation of BCCs.
The efficacy and safety of sonidegib were previously
evaluated in patients with laBCC or mBCC in the BOLT
study.5,6 The approved sonidegib dose of 200 mg daily
achieved an objective response rate (ORR) by central
review (95% confidence interval [CI]) of 43% (28%–59%)
and 15% (2%–45%) in patients with laBCC and mBCC,
respectively, after up to 6 months of treatment.5 In follow-
up results at 42 months, sonidegib 200 mg daily maintained
its efficacy profile with ORR per central review (95% CI) of
56.1% (43.3%–68.3%) and 7.7% (0.2%–36.0%) in laBCC
and mBCC, respectively.6 The most common AEs at 42
months in patients (n [%]) receiving sonidegib 200 mg
daily included muscle spasms (43 [54.4%]), alopecia (39
[49.4%]), and dysgeusia (35 [44.3%]).6 Guidelines were
established for the management of AEs using dose
interruptions.5
Vismodegib (Erivedge®, Genentech, San Francisco,
CA), a HPI, was evaluated at a dose of 150 mg daily vs
placebo in a randomized, double-blind, phase 2 study in
patients with NBCCS.7 Treatment with vismodegib led to
a significantly reduced mean rate of appearance of surgi-
cally eligible BCCs vs placebo (2 vs 34 new BCCs per
patient per year, respectively, P <0.0001). After disconti-
nuation of vismodegib, the rate of appearance of new
surgically eligible BCCs was not significantly different
from the placebo group (0.06 vs 0.12 new BCCs per
month for vismodegib vs placebo, respectively, P =
0.06). AEs in the vismodegib group—including alopecia
(100%), muscle cramps (100%), and dysgeusia (93%)—
limited the use of vismodegib and led to discontinuation in
19 of 25 patients at 1 study site (76%).7 The prevalence of
these AEs in the current study was lower when compared
with BOLT and the study of vismodegib in NBCCS,
potentially due to shorter treatment duration or smaller
patient numbers.
Limitations of the current study include the small sam-
ple size, with only two patients in the placebo arm, which
contributed to limited statistical evaluation of efficacy and
safety results. In 37.5% of patients receiving sonidegib,
tumor histology was unknown. In addition, efficacy out-
comes were assessed at 16 weeks of treatment, which may
have been too short to fully assess the clinical effects of
sonidegib in patients with NBCCS. Reporting of standard
oncological measures, such as objective response rate and
best overall response, would contribute to a more complete
assessment of sonidegib efficacy in NBCCS; however, the
small sample size, short duration, and exploratory design
of the study may limit the conclusions that can be drawn
from these measures.
This is the first report demonstrating the efficacy and
safety of sonidegib in NBCCS. Sonidegib showed promis-
ing efficacy as demonstrated by partial or complete clinical
clearance of target BCCs and decreased tumor burden in
all patients, and histological clearance in 57% of the
patients. Overall, sonidegib appeared well tolerated.
Further studies are needed to thoroughly evaluate the
sonidegib safety and efficacy trends observed in patients
with NBCCS.
Data Sharing Statement
Data and other documents will be made available after
publication, with no end date, to anyone who submits
a reasonable request to the study sponsor.
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